The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 18 May 2004, www.theannals.com, DOI 10.1345/aph.1D624.
 The Annals of Pharmacotherapy: Vol. 38, No. 7, pp. 1197-1201. DOI 10.1345/aph.1D624
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramasubbu, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramasubbu, R.

SSRI Treatment–Associated Stroke: Causality Assessment in Two Cases

Rajamannar Ramasubbu, MD FRCP(C)

Assistant Professor, Department of Psychiatry, University of Calgary, Foothills Medical Centre, Rm. AW258A, 1403 29th St. NW, Calgary, Alberta T2N 2T9, Canada, fax 403/270-3451, rramasub{at}ucalgary.ca

Reprints: Rajamannar Ramasubbu MD FRCP(C)

OBJECTIVE: To assess the probability of cerebrovascular adverse drug reactions (CV-ADRs) due to treatment with selective serotonin-reuptake inhibitors (SSRIs) using 2 causality methods.

CASE SUMMARIES: Two patients with the possibility of SSRI-related stroke were referred for causality assessment. Causality assessment was performed using an adverse drug reaction probability scale, as well as clinical and radiologic parameters. A 31-year-old white man, who had been receiving paroxetine 200 mg/day over a period of 3 years, developed ischemic stroke involving left middle cerebral artery. The second patient was a 46-year-old white woman with a history of recurrent depression who developed delirium and ischemic stroke while she was taking a combination of paroxetine 50 mg/day, trazodone 200 mg/day, and bupropion 150 mg/day.

DISCUSSION: Carotid and cardiothromboembolism were found to be the major etiological factors for ischemic stroke. Accounting for the temporal relation, prior reports of SSRI treatment–associated CV-ADRs, and the pharmacologic action of serotonin on coagulation and the vascular system, the possible contribution of SSRIs to stroke in these patients was considered. An objective causality assessment using the Naranjo probability scale revealed that a CV-ADR was possible. However, the nature of the stroke, plus clinical and radiologic findings, were inconsistent with known pathophysiologic mechanisms linking SSRIs and stroke in these patients.

CONCLUSIONS: Causality assessment may improve unbiased recognition, management, and voluntary reporting of infrequent adverse effects such as SSRI treatment–related cerebrovascular accident.

Key Words: selective serotonin-reuptake inhibitors, stroke

Published Online, May 18, 2004. www.theannals.com, DOI 10.1345/aph.1D624


This article has been cited by other articles:


Home page
 NeurologyHome page
O. Noskin, E. Jafarimojarrad, R. B. Libman, and J. L. Nelson
Diffuse cerebral vasoconstriction (Call-Fleming syndrome) and stroke associated with antidepressants.
Neurology, July 11, 2006; 67(1): 159 - 160.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.